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Rapport de Synthèse 
La thérapie antirétrovirale a progressée de manière significative depuis le 
début de l'épidémie du syndrome d'immunodéficience acquise (SIDA). Durant les 20 
dernières années, plusieurs combinaisons de traitements ont été utilisées avec 
succès menant à une réduction de la mortalité associée. Par contre, le traitement a 
aussi engendré des cas de résistances multiples avec comme résultat, le besoin 
d'utiliser plusieurs molécules en combinaison, et une augmentation des cas de 
toxicité. Une stratégie souvent employée fût la combinaison de deux molécules 
inhibitrices de la protéase en même temps en combinaison avec une troisième 
molécule, le ritonavir. (DBPI). 
La cohorte Suisse sur le VIH existe depuis 1987 et permet d'étudier de façon 
longitudinale les patients qui y sont inscrits. Pour ce travail de thèse, nous avons 
étudié les patients inscrits à la cohorte suisse de 1996 à 2007 qui ont reçu une 
combinaison DBPI. 
Pendant la période étudiée, un total de 405 patients ont reçu un traitement 
DBPI, dont 295 patients ont reçu le DBPI pour plus de 6 mois. La durée médiane du 
traitement était de 2.2 ans. Sur les 287 patients qui étaient en échec viral au début 
du traitement (défini comme HIV RNA>400 copies/ml), 64.1% ont réussi à supprimer 
la virémie et 54.4% ont eu une suppression dans les 24 semaines qui ont suivi le 
début de la thérapie. Les patients avaient reçu en moyenne 6 combinaisons de 
traitement différentes avant le début de la thérapie DBPI. Pour le~ patients qui ont 
arrêté le traitement DBPI, la cause principale de l'arrêt était due au souhait du 
patient (48.3%), à l'échec virologique (22.5%) et à la toxicité {15.8%). 
Les patients ayant reçu le traitement après 1999, ou ayant été traités avec une 
combinaison de Lopinavir-ritonvir/saquinavir ou lopinavir-ritonavir/atazanavir 
arrivaient à supprimer leur virémie plus souvent que ceux qui avaient reçu d'autres 
combinaisons. 
Cette étude constitue la plus grande étude publiée sur le sujet de l'utilisation 
des DBPI pour les patients à résistances multiples. Malgré le fait que c'est une étude 
observationnelle, nous pouvons attester que le taux de succès était de 64.4%, le taux 
de toxicité était relativement bas (15.8%) et que la plus part des patients ont toléré 
ces combinaisons, malgré le taux élevé d'effets secondaires souvent rapportés. En 
somme, cette approche pourrait être envisagée,dans des situations ou les nouveaux 
traitements tels que les inhibiteurs de l'intégrase et du ,CCR5 ne sont pas encore 
disponibles. 
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Abstract 
Background: Dual-boosted protease inhibitors (DBPI) are an option for salvage therapy for HIV-1 resistant 
patients. 
Methods: Patients receiving a DBPI ·in the Swiss HIV Cohort Study between Januaryl996 and March 2007 were 
studied. Outcomes ?f interest were viral suppression at 24 weeks. 
Results: 295 patients (72.5%) were on DBPI for over 6 months. The median duration was 2.2 years. Of 287 
patients who had HIV-RNA >400copies/ml at the start of the regimen, 184 (64.1%) were ever suppressed while 
on DBPI and 156 (54.4%) were suppressed within 24 weeks. The median time to suppression was 101 days (95% 
confidence interval 90-125 days). The median number of past regimens was 6 (IQR, 3--8). The main reasons for 
discontinuing the regimen were patient's wish (48.3%), treatment failure (22.5%), and toxicity (15.8%). Acqui-
sition of HIV through intravenous drug use and the use of lopinavir in combination with saquinavir or ata-
zanavir were associated with an increased likelihood of suppression within 6 months. 
Conclusion: Patients on DBPI are heavily treatment experienced. Viral suppression within 6 months was 
achieved in more than half of the patients. There may be a place for DBPI regimens in settings where more 
expensive altemates are not available. 
Introduction 
ANTIRETROVIRAL THERAPY HAS UNDERGONE MANY CHAN-GES over the course of the last 20 years and has resulted in 
decreased morbidity and mortality among HIV-infected pa-
tients.1 However, in clinical practice, factors such as poor ad-
herence, limited potency of prior regimens, and drug toxicity 
have led to an increased prevalence of multiple resistance mu-
tations in bath reverse transcriptase and protease sequences.2 
Treatment options after the accumulation of several pro-
tease inhibitor (PI) mutations are limited and usually require 
the use of newer agents such as integrase inhibitors (ralte-
gravir [RAL], salvage Pls (tipranavir [TPV], and darunavir 
[DRV]), new generation non-nucleoside reverse transcrip-
tase inhibitors (NNRTis) such as etravirine (ETV) or entry 
inhibitors (fusion [T-20] or CCR5 inhibitors (maraviroc 
[MVC]).3 Before the availability of these new drugs, many 
clinicians used different salvage strategies in the treatment of 
1Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland. 
2Data Coordination Center for the Swiss HIV Cohort, Lausanne, Switzerland. 
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. 4university of Basel, Medicine, Division of hûectious Diseases, Basel, Switzerland. 
5universitiitsspital Bern, Klinik und Pol.iklli;tlk für Infektiologie, Bern, Switzerland. . . 
6university Hospital Zürich, Division of Infectious ·Diseases and Hospital Epidemiology, University of Zürich, Switzerland. 
70spedale, Civico, Department of Medicine, Division of Infectious Diseases, Lugano, Switzerland. 
8
.Kantonsspital St. Galien, Sw'itzerland. . . · 
9The Reproductive Health and HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. 
Part of the results (poster P7.4/06) were presented at the 11 th European Aids Clinical Society (EACS) Conference in Madrid, Spain, October 
24"-27, 2007. . 
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multidrug~resistant HIV. Sorne of these regimens included 
two PI in addition to low-dose ritonavir (RTV, dual-boosting). 
RTV, a potent inhibitor of the cytochrome P450 enzymatic 
system, is extensively used as an adjunct to PI therapy (as a 
booster).4 The increase in levels of co-administered PI due to 
this drug-drug interaction has allowed for simpler and less 
toxic regimens to be adopted for the treatment of HIV.5 In 
addition, the enhanced pharmacokinetic profile (in particular, 
Cmin and Area Under the Curve, AUC) of the boosted drug 
enables better viral suppression6 and a higher threshold for the 
development of resistance than if used without RTV.7-9 De-
spite early studies showing marginally increased side-effects,5 
boosted PI therapy has become part of the standard of care for 
the treatment of naïve and experienced patients,10'11 particu-
larly becauseDf their high genetic barrier to resistance.12- 14 
Similarly, the use of dual-boosted regimens has gained fa-
vor due to some studies reporting on synergistic and additive 
effects of PI combinations with little additive toxicity.15- 21 In 
addition, the concept of maintaining high plasma levels of two 
drugs, with distinct resistance profiles, will enable each drug 
to retain activity against the susceptible viral quasi-species in 
the presence of multiple PI resistance mutations is appealing. 
This approach has become more popular in recent years 
with the approval of atazanavir (A TV), which has less meta-
bolic toxicity22 and therefore is deemed safer when used in 
addition to conventional Pis. Several pharmacokinetic studies 
have also shown that double-boosted protease inhibitors 
(DBPI) have a relatively safe profile, especially ATV co-ad-
ministered with saquinavir (SQV) or lopinavir / ritonavir 
(LPV-r).16,19'20 23 Few clinical observational studies showed 
that ATV combined with LPV-r23 was well-tol~rated and ef-
ficient in patients with extensive treatment experience. 
Although former recommendations issued by the interna-
tional AIDS society-USA panel stated that "there are no 
convincing data to support the use of a DBPI and these regi-
mens should be avoided",24 DBPI regimens were used widely 
in clinical practice due to lacking alternatives in salvage 
therapy. Despite this assertion, there are very few published 
studies regarding outcomes in large cohorts, and a recent 
small randomized controlled trial favored DBPI in an as-
treated analysis.25 There will likely never be a large trial to 
determine the relative efficacy and toxicity of the multitudes 
of combinations of DBPI available which could refute or 
confirm this hypothesis. Nevertheless, one needs to consider 
that in many parts of the world, widespread roll-out of anti-
retrovirals with low frequency of viral load monitoring is 
leading to the emergence of severe drug resistance. In addi-
tion, potent anti-retrovirals such as integrase inhibitors and 
new generation NNRTis are unfortunately not yet available in 
most resource-constrained settings. 26---28 This means that DBPI 
regimens may be the only salvage regimens available in pa-
tients who have multi-class failure in some countries. We 
therefore aimed to characterize the patients who have re-
ceived DBPI regimens within the Swiss Brv Cohort Study 
(SHCS) and to identify independent factors predicting viral 
suppression.at 6 months on a DBPI regimen. 
Methods 
Study design 
This is a retrospective analysis of data recorded in the 
context of a prospective observational cohort of all patients 
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enrolled in the SHCS since its inception (1987) and who re-
ceived a treatment regimen containing RTV and two other Pis 
between January 1996 and March 30, 2007. 
The SHCS is a longitudinal cohort that collects information 
on a bi-annual basis on more than 14,000 patients from seven 
participating centers in Switzerland. The detaileQ. structure of 
the SHCS has been described elsewhere.29'30 We collected 
data on demographical information and results of laboratory 
tests at cohort visits (CD4cell count, HIV-1 RNA, and lipid 
profiles), treatment regimens, and reasons for switching 
regimens. 
Definitions 
• DBPI was defined as the use of RTV in combination with 
two other Pis. Patients who received nelfinavir (NFV) in 
this combination were also included in the study, despite 
evidence that NFV is not significantly boosted by RTV. 
Patients who received newer Pis in salvage therapy, no-
tably DRV and TPV, were excluded from the study. We 
also did not consider full-dose RTV in combirlation with 
SQV as a DBPI equivalent and therefore excluded pa-
tients on this particular combination from the study. 
• HIV RNA suppression was defined as a viral load of 
<400copies/tnl. We chose this cutoff because it most 
accurately identifies all episodes of suppression across 
the time-span chosen within the cohort. Cutoffs for 
suppression were changed during the 10 years of ob-
servation that we chose (from <400copies/tnl to 
<20 copies/ml) with the final cutoff recorded in the 
cohort being dependent on the laboratory method used 
at a given time. Additionally, patients who were con-
sidered suppressed were assigned an RNA value of zero 
in the database and therefore the real value for these 
patients cannot be determined retrospectively. 
Laboratory values 
CD4 count and HIV RNA viral load at cohort entry were 
defined as the first value recorded within the cohort. These 
values do not necessarily represent the laboratory values 
present at the time of HIV-1 diagnosis for each patient. 
CD4 count and HIV RNA viral load at the time of DBPI 
start were calculated within a time range so as to most accu-
rately reflect the values available to the clinician. For CD4 
counts, we considered all values within 30 days of the eventof 
interest (cohort start, DBPI start, DBPI stop, cohort exit) and 
chose the value closest to the date of the event within those 30 
days. Since HIV RNA is more often used fol'clinical decision 
making, we took into consideration values thatwere closest to 
the sixth month after DBPI start, up to 30 days before but no 
more than 10 days after. The value of HIV-RNA up to 10 days 
after the cohort visit would be an accurate reflection of the 
value available to the clinician at the time clinical decision-
~aking occurred. 
For HDL and cholesterol values, we chose the value.that 
was closest to the event of interest, either before or after the 
event but within 30 days. 
Treatment in(erruptions and changes 
Any instance where the patient recorded as not being on 
therapy either before or after the regimen of interest was 
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considered as a treatment interruption, regardless of the du-
ration or reason for the treatment interruption (intercurrent 
illness, physician' s decision or patient' s decision for example). 
The number of regimen changes was calculated based on 
the change of any drug within the regimen, and was not 
limited to the PI class. 
The duration of zidovudine (AZT) monotherapy and nu-
cleoside reverse transcriptase inhibitors (NRTI) bi-therapy 
alone is based on the cumulative time the patient received 
these regimens, irrespective of treatment interruptions within 
this time. However, patients had to have gone back to the 
original regimen in order for the time to be ip.cluded (i.e., 
patients who switched from AZT to bi-therapy and then back 
to AZT were not considered to be on AZT monotherapy for 
that entire time period). NNRTI experience was defined as the 
receipt of a regimen containing efavirenz (EFV), nevirapine 
(NVP), or delavirdine (DL V) before the onset of the DBPI 
regimen, regardless of the concomitant drugs in the regimen. 
NNRTI co-administration was defined as the req:dpt of EFV 
or NVP in conjunction with the DBPI regimen. 
Outcomes 
Outcomes of interest were characteristics of the patients 
who received DBPI, particularly for those who received the 
regimen for less than 6 months versus those who continued 
the regimen for longer periods, time to viral suppression for 
ail patients included in the study, and the proportion of pa-
tients who achieved a viral suppression in less than 180 days 
after the start of the DBPI regimen. In addition, factors asso-
ciated with duration of DBPI therapy were investigated. 
Statistical analysis 
Simple descriptive statistics were used to describe the 
study population. To compare the group that achieved sup-
pression to the one that did not, the Pearson chi-square test 
was used for categorical data, as well as Fisher's exact test 
when required, and Student t-test, as well as Wilcoxon rank 
sum test for continuous data. The logistic regression model 
was used for dichotomous outcomes. Adjustment was per-
formed for at most one or two factors 11t a time to assess 
conditiànal associations. No specific model selection was 
performed and results are mainly descriptive. 
Results 
Baseline characteristics 
We identified 407 patients who received DBPI during the 
study period and 295 patients who received DBPI for at least 6 
months. Patients who received more than 6 months of treat-
ment and those who stopped early did not differ significantly 
in age, gender distribution, inode of HIV acquisition, regi-
mens used, or cohort outcome. However, patients who re-
ceived DBPI for longer than 6 months tended to be diffetent 
from those who stopped the treatment earlier regarding HIV 
RNA at DBPI start (4.6 log vs. 3.6 log, p < 0.01), mean CD4 
counts at enrollment (260 vs. 356.5, p =0.02 [not irnportantly 
significant]), and ·a tendenèy for lower CD4 count at DBPI 
start (187 vs. 225, p = 0.05, idem). Moreover, more patients 
were experiencing virological failure at the time cif DBPI start 
in the group who pursued treatment for more than 6 months 
(73.6% vs. 61.6%, p = 0.02). The two groups also differed with 
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respect to treatment experience before DBPI start. Patients 
who stopped early (<6 months) had been on antiretroviral 
treatment for a median of 5.9 years (interquartile range [IQR] 
3.1-8.8) compared to 7.3 years (IQR 4.9-9.2) in patients who 
continued DBPI. for longer (p < 0.01). 
Characterization of DBPI group 
We will then describe the 295 patients who underwent 
DBPI treatment for at least 6 months. They had a m.edian age 
of 43 years (IQR: 38-49) and were mostly male (76.9%, 
n = 227). The most common risk factor for HIV acquisition 
was men-havingcsex-with-men (MSM) (43.4%, n = 128), fol-
lowed by heterosexual contact (29.8%, n = 88), and intrave-
nous drug use (23.1%, n=68). Eleven patients had either an 
unknown risk factor or acquired HIV through blood trans-
fusions. A total of 248 patients (84.1 % ) were still active in the 
cohort at the time of the last follow-up visit. Thirty-three pa" 
tients died (11.2%) since they were first enrolled between 
January 1996 and March 30, 2007 and only 14 (4.7%) had 
either withdrawn from the SHCS or were lost to follow-up on 
March 30, 2007. The cause of death was related to HIV in 17 
patients (5.8%). Table 1 summarizes the characteristics of the 
patients as. well as the treatment experience before starting 
therapy. 
Treatment interruptions 
To better characterize the treatment experience of our co-
hort, we analyzed the number of treatment interruptions that 
had occurred before the start of DBPI as well as the number of 
regimen changes before and after the DBPI regimen. Ninety 
patients (30.5%) had never interrupted their treatment before 
starting the DBPI regimen, 102 patients (34.6%) had inter-
rupted a regimen once, while 94 (31.9%) had done so two to 
five times. There were 9 patients (3.1 %) who had between six 
and ten treatment interruptions prior to starting DBPI. For the 
regirnen changes, 135 patients (45.8%) experienced between 
one and five regimen changes prior to starting DBPI. 116 
(39%) had 6-10 changes and 33 (11.2%) had 11-15 changes. 
There were 9 patients (3.1 % ) who had more than 15 different 
regimens from the time of enrollment. The median number of 
changes after the DBPI regimen was 2 (IQR:l--4) (Table 1). 
DBPI regimens used and duration on therapy 
LPV-r was the most common PI used in our DBPI cohort. A 
total of 240 (81.4%) patients were receiving LPV-r in combi-
nation with one other PI. The most common combination was 
LPV-r/amprenavir (LPV-r/APV) used in 110 (37.3%) pa-
tients, followed by LPV-r/SQV in 82 (27.8%) patients, SQV-r / 
ATV was given to 36 (12.2%) patients. Eighty-eight (29.8%) 
patients also received concomitant NNRTI and 19 ( 6.4 % ) were 
receiving fusion inhibitors. The number of drugs in the regi-
rnen ranged from three to more than six, with 129 patients 
rèceiving four drugs (43.7%) and 15 (5.1 %) receiving more 
than six drugs concomitantly .. We subdivided the cohort ac-
cording to the year DBPI therapy was begun and found that 
227 (76.9%) patients had started DBPI after the year 2000 and . 
only 68 patients had been started on a DBPI regimen before 
the year 2000 (Table 2). 
The DBPI regimen was stopped in 120 (40.7%) patients 
before the end of the follow-up period. The most common 
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TABLE 1. BASELINE CHARACTERISTICS AND TREATMENT EXPERIENCE OF PATIENTS ON DuAL-BOOSTED PROTEASE 
INHIBITORS IN THE Sw1ss HIV CoHORT STUDY, JANUARY 1996--MARCH 2007 
Variable (unit) 
Time from ART start to DBPI start (years) 
Median time on DBPI 
Days 
Years 
CD4 Nadir (median, cells/mm3) 
D4 at start of cohort (median, cells/mm3) 
CD4 at last follow-up or exit (median, cells/mm3) 
RNA at start of cohort (log10) 
RNA at shirt of DBPI treatment (log10) 
Azt monotherapy exposure 
NRTI bi-therapy 
Single PI exposure before starting DBPI 
NNRTI exposure before starting DBPI 
RTV-SQV experience before DBPI start 
Number of treatment interruptions 
before DBPI start (median) 
None 
One 
Two--Five 
Six-Ten 
Number of regimen changes before DBPI start 
None 
1-5 
6--10 
11-15 
>16 
Number of Changes after DBPI stop 
DBPI Regimen 
Containing LPV / r 
Containing SQV 
Containing RTV 
Containing APV 
Containing ATV 
Containing IDV 
Containing fos-APV 
Concomitant NNRTI 
Concomitant T-20 
Number of drugs in regimen 
2 
3 
4 
5 
2:6 
reason for stopping was provider decision or patient prefer-
ence (48.3%, 11=58). Treatment failure accounted for the 
withdrawal of the regimen in 27 (22.5%) and toxicity in 19 
(15.8%) patients. In these 19 patients, dyslipidemia, elevated 
cardiovascular risk, and abnormal fat distribution prompted 
1 
the regimen change in 8 (42.1%) cases, and GI symptoins, 
including elevated liver enzymes, were present in 7 (36.9%). 
The remaining 4 patients discontinued due to endocrine, 
nervous system, or other unspecified toxicities. 
Of note when compared to the group of patients who had 
early swit.ches and never received DBPI for longer than 6 
months, toxicity accounted forthe treatmentwithdrawalin 29 
(35.4%) of the 112 patients. This difference was statistically 
significant ( p = 0.02). There were no significant differences in 
Ali patients DBPI > 6 months 
N=407 (%), [IQR] N = 295 (%), [IQRJ 
7.0 (4.4-9.1) 7.3 (4.9~9.2) 
520 (159-1126) 799 (421-1443) 
1.4 (0.4-3.1) 2.2 (1.2-3.9) 
66 (20-151) 61 (16--136) 
286 (134-470) 260 (120-445) 
360 (163--533) 361 (183--539) 
4.6 (3.5--5.2) 4.7 (3.7-5.2) 11=240 
4.6 log (3.4-5.2] 
198 (48.9) 153 (52) 
265 (65.4) 201 (68.1) 
332 (81.9) 25i (85.4) 
250 (61.7) 181 (61.6) 
179 (44) 134 {45.4) 
1 [0-2] 1 [0-2] 
116 (28.5) 90 (30.5) 
137 (47.1) 102 (34.6) 
142 (48.8) 94 (31.9) 
12 (4.1) 9 (3.1) 
6 [3-9] 6 [ 3-8] 
24 (9.4) 15 (5.1) 
172 (42.3) 122 (41.4) 
152 (37.3) 116 (39.0) 
49 (12.0) 33 (11.2) 
10 (2.5) 9 (3.1) 
2 [1-4] 2 [1-4] 
318 (78.1) 240 (81.4) 
174 (42.7) 130 (44.1) 
104 (25.5) 58 (19.7) 
141 (34.6) 116 (39.4) 
96 (23.6) 63 (21.4) 
41 (10.1) 17 (5.8) 
14 (3.4) 13 (4.4) 
111 (27.3) 88 (29.8) 
25 (6.1) 19 (6.4) 
16 (3.9) 13 (4.4) 
101 (24.8) 84 (28.5) 
179 (44.0) 129 (43.7) 
84 (20.6) 54 (18.31) 
27 (6.6) 15 (5.1) 
the group who stopped early compared to the group who 
received treatment for over 6 months with respect to patient 
or provider preference as a reason for stopping the regimen or 
the occurrence of virological failure. 
Virological response to D8PI treatment 
Virological suppression defined as a HIV RNA <400cop-
opies/ml was observed in 184 (64.1 %) of the 287 patients who 
had a virological failure at the start of the DBPI regimen and 
156 (54.4%) achieved suppression within24 weeks of starting 
the regimen. Of all 287 patients, 170 (79.1 % ) who are still in the 
cohort by the end of May 2009 were suppressed at their last 
follow-up appointment and 148 (68.8%) had an HIV-RNA of 
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TABLE 2. CHARACTERISTICS OF PATIENTS WHO ACHIEVED SUPPRESSION IN LESS THAN 6 MONTHS AND WHO RECEIVED 
MoRE THAN 6 MoNTHS OF DBPI, AND WERE FAILING THERAPY AT THE START oF DBPI 
RNA < 400 copies/ml RNA> 400copies/ml 
Variable N = 141 (%), [IQRJ N = 77 (%), [IQR] P value 
Age 43.9 [38-49] 42 [37-46] 0.11 
0.13 Ethnicity (Caucasian) 120 (85.1). 71 (92.2) 
Gender (male) 107 (75.9) 63 (81.2) 
Riskgroup 0.01 
Heterosexual 46 (32.6) 21 (27.7) 
IDU 41 (29.1) 10 (12.9) 
MSM 49 (34.7) 42 (54.6) 
Other 5 (3.6) 4 (5.2) 
Mortality 10 (7.1) 17 (22.1) 
CD4 at start of DBPI (median) 184.4 (73.5-256.5) 162.3 (21-242) 
0.0013 
0.081 
CD4 Category at start 
<200cells/ml 73 (58.9) 46 (65.7) 0.51 
200-350 cells /ml 38 (30.6) 16 (22.9) 
>350cells/ml 13 (10.5) 8 (11.4) 
CD4 at cohort entry (median) 295.7 (79-390) 341.5 (174-450) 0.013 
0.045 
0.0011 
VL at cohort entry (log10) 4.41 (3.9-5.1) 4.68 (4.1-5.2) 
VL at start of DBPI (log10) 4.56 (3.7-5.2) 4.95 (4.7-5.4) 
Treatment year (start) 
1996--1999 2 (1.4) 
2000-2002 72 (51.1) 
2003-2004 44 (31.2) 
>2004 23 (16.3) 
Year of DBPI start 
Before 2000 28 (19.9) 
After 2000 113 (80.2) 
RTV-SQV before DBPI start 57 (40.4) 
AZT monotherapy (received) 76 (53.9) 
NRTI bitherapy (received) 95 (67.4) 
Regimen used 
LPV-r/AMP 58 (41.2) 
LPV-r/SQV 43 (30.5) 
LPV-r/ATV 9 (6.4) 
LPV-r/fos-AMP 6 (4.3) 
SQV/RTV 18 (12.8) 
SQV-r/AMP 1 (0.71) 
Number of regimen changes 
0 1 (0.7) 
1-5 68 (48.2) 
6--10 55 (39.0) 
>11 17 (12.1) 
Number of treatment interruptions 
0 38 (26.9) 
1-2 77 (54.6) 
>2 26 (18.4) 
less than 50copies/ml at their last follow-up. The median 
time to suppression was 101 days (95% confidence interval, 
95% CI: 90-125 days). 
We compared the baseline characteristics of the patients 
who achieved suppression in the first 24 weeks and those who 
did not in an "intention to treat analysis" (i.e., irrespective of 
the treatment duration). Patients who achieved suppression 
were more likely to be intravenous drug users (p = 0.01), had 
a lower CD4 at cohort entry (p = 0.01), and a lower HIV-RNA 
at the start of DBPI therapy, and were more Iikely to start 
DBPI after the year 2000. In terms of outcomes, patients who 
did not achieve suppression had a highermortality (22.1% vs. 
7.1%, p=0.001), and had a lower medfan CD4 gain during 
8 (10.4) 
48 (62.3) 
14 (18.2) 
7 (9.1) 
33 (42.9) 
44 (57.1) 
44 (57.2) 
44 (57.1) 
55 (71.4) 
41 (53.2) 
11 (14.3) 
1 (1.3) 
3 (3.9) 
15 (19.5) 
2 (2.6) 
0 
34 (44.2) 
24 (31.2) 
19 (24.7) 
19 (24.7) 
41 (53.2) 
17 (22.1) 
0.002 
0.0003 
0.02 
0.64 
0.54 
0.09 
0.008 
0.09 
0.99 
0.23 
0.28 
0.09 
0.79 
therapy ( +96.6 vs. + 195.2 cells/mm3, p < 0.0001). These pa-
tients also differed significantly in terms of exposure to SQV-
RTV before starting DBPI and the use of LPV-r/SQV as a 
DBPI regimen (Table 2). 
Toxiclty 
Regarding toxicity of DBPI, there was no significant dif-
ference in lipid values before and after treatment in the 120 
patients who ]}ad a lipid profile available within 100 day~ of 
starting or stopping the DBPI regimen. The mean change in 
cholesterol values before and after DBPI therapy was 
-0.49 mmol/l (95% CI: -0.96 to -0.02; p = 0.05) and the.mean 
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TABLE 3. MuLTIPLE Loc1snc REGRESSION: FACTORS AssocrATED wrTH EARLY SuPPRESSION (<24 WEEKs) 
IN PATIENTS WHO RECEIVED DBPI THERAPY AND RAD HIV RNA >400COPIES/ML AT START OF DBPI 
In all patients n = 287 
ln patients who received therapy 
for >6 months, n = 218 
Variable OR (95% CI). 
HIV-1 RNA at start 
Treahnent before 2000 0.10 (0.023--0.46) 
Intravenous drug use 2.29 (1.26--4.18) 
Regimens used 
Lopinavir-r / Atazanavir 3.95 (1.06--14.72) 
Lopinavir-r /Saquinavir 2.04 (1.10---3.65) 
change in HDL was +0.04mmol/l (95% CI -0.08 to 0.09; 
p=0.89). 
Factors associated with virologicaf response 
A multivariable regression model was built to determine 
which factors were associated with early suppression in bath 
patient groups. We showed that the transmission of HIV 
through intravenous drug use, the start of DBPI after 1999 as 
well as the use of LPV-r/SQV and LPV-r/ ATV were all in-
dependently associated with an early suppression of HIV-1 
RNA. However, in patients who received DBPI for longer 
than 6 months, HN-1 RNA at treahnent start was strongly 
associated with early suppression (OR 0.49 95% CI 0.33--0.75, 
p =0.0008 but treahnent with LPV-r/ ATV was not (Table 3). 
Discussion 
To our knowledge, our study is the largest published ta 
date describing the use of DBPI in extensively treahnent-
experienced patients in detail. Several previous studies 
attempting to evaluate the effectiveness of DBPI in HIV treat-
ment have been discontinued25 and a prospective trial is un-
likely to be undertaken given the newer regimens available 
for therapy. 
Our analysis shows that patients who received LPV-r/SQV 
as part of their DBPI regimen were more likely to achieve 
suppression, especially when the year of initiation of DBPI 
therapy was after 2000. This may also be related to the intro-
duction of newer NRTis such as tenofovir or abacavir, which 
may have retained some activity in patients who had thymi-
dine analog mutations from expostrre to single or dual NRTI 
regimens in the past. Of the patients who continued to receive 
DBPI, the proportion who achieve virologie suppression 
(64,1 %) was comparable and in some instances, better than, 
those described in treatment-naïve studies in the earlier years 
of HIV treatment.31 Our findings also suggest comparable 
suppression rates than in "real-life" settings with othet salvage 
approaches studied in randpmized controlled trials such as the 
use of newer Pls, NNRTis, .and integrase inl;ùbitors with op-
timized background regimens.32-34 In addition, the concomi-
tant use of NNRTI did not inflrtence the outcome and both 
NNRTis and enfuviritide were used by a minodty of patients 
(20.5% and 5.4%, respectively). In this study, 64.6% of the 218 
patients who started a DBPI due to virological failure and 
continued the treatment for longer than 6 months, achieved a 
viral load of <400copies/ml. All the patients were heavily 
P value OR (95% CI) P value 
0.49 (0.33--0,75) 0.0008 
0.003 0.08 (0.01--0.44) 0.04 
0.007 2.32 (1.04-5.14) 0.04 
0.04 
0.003 2.56 (1.16-5.62) 0.02 
treahnent experienced, with an average of six regimen changes 
before starting a DBPI regimen. Patients infected through in-
travenous drug use show better virological suppression. This 
may be·explained by the fact that patients who are current 
intravenous drug users are more often directly observed and 
therefore may have better adherence tl\.an other patients in the 
cohort. While toxicity was not an issue for patients who con-
tinued on DBPI for longer than 6 months, it was a significant 
reason to stop early, indicating thereby that early toxicity is a 
barrier to wider use of DBPI (at a mean time of 41 days, [IQR 
10.5--95]). In addition, tj-te patients who stayed on DBPI for 
longer than 6 months had a lower CD4 count, a higher viral 
load and were more treahnent-experienced at the start of DBPI 
compared to those who discontinued the treatment earlier. 
This may represent a treahnent bias towards maintenance of 
DBPI regimen in patients with a more advanced disease and 
higher risk for progression to AIDS. 
Several small series have been published and suggested that 
DBPI-based salvage regimens may be berieficial to patients and 
were responsible offew toxicity.35--38 In contrast, Petersen et al. 
published results from a retrospective cohort study comparing 
the efficacy of DBPI versus boosted single PI therapy in 183 and 
805 patients, respectively, and concluded that there was no 
statistically significant benefit to use DBPI for salvage therapy. 
However, the findings did suggest that there may be a mod-
erate size benefit if the cohort had been larger.39 The authors 
also point out the limitations of using a retrospective analysis of 
data compared to the gold standard of a randomized double- · 
blind clinkal triai. Similarly, Loutfy et al. foµnd that the addi-
tion of APV to a salvage regimen containing LPV /r was not 
associated with a faster time to achieve virological suppression 
n,or with a difference in virological rebound rates.40 Another 
recent clinical trial in Thailand reported on 50 treabnent-
experienced children who received SQV in combination to 
LPV /rand found that there was significant rise in CD4 counts 
and viral suppression <400 and <pO at 48 weeks was achieved 
in 78% and 64% of cases, respectively.41 An earlier study by the 
s~me group found that the pharmacokinetic profile of this 
regimen was favorable inchildren.42 However,APV or SQV in 
combination with LPV / r have fallen out of favor in recent years 
due to the side-effect profile on lipids as well as due to the high 
pill-burdèn, leading to. a risk of reduced adherence. In addition, 
results on pharmacokinetic interactions of APV and LPV / r 
have produced conflicting results. Fosamprenavir, in combi-
nation with LPV/r, has also shown to have antagonistic 
pharmacokinetic profiles and LPV / r reduces fAPV levels.25 
OUTCOMES OF DUAL·BOOSTED PIS 
The conflicting results published so far on the general use of 
DBPI may also have been related to the side-effect profile and 
potency of the individual Pis studied, while studies using 
newer agents were more likely to report positive findings.23 
More recently, a review of published studies on DBPI con-
cluded that those combinations may play a positive role in 
settings where other drugs are not available.43 
Our study presents several limitations due to its observa-
tional nature exposing to potential misclassification and se-
lection bias. Patients were first not randomized and were not 
compared to a controlled group, leading to the risk of selection 
bias as information bias. Second, adherence data has. only 
systematically been collected in the SHCS since 2003,44 and 
thus was not available for this study. Third, genotypic drug · 
resistarice information was not sufficiently available for the 
current study because genotyping was only prospectively 
used widely after introduction into the SHCS in the year 2000.2 
However, one may argue that at the time when DBPI regimens 
were widely instituted, genotypic drug resistance information 
was only sparsely available, exactly reflecting the situation as 
it presents today in the developing countries, where drug re-
sistance testing will not be routinely available in the near fu" 
ture. These countries however are exactly the ones that might 
have to depend mostly on DBPI treatments for salvage in the 
future. In addition, the main criticism against the use of DBPI 
in clinical practice was its potential for higher toxicity, espe-
cially regarding the higher risk for cardiovascular morbidity. 
We were able to report before and after lipid profiles in only 47 
patients, and even though this did not have any significant 
increase in cholesterol, a more in-depth study would be nec-
essary to confirm these results. A retrospective pharmacoki-
netic analysis performed on stored serum samples could have 
yielded more information on drug levels and the exact nature 
of drug interactions. Howevet, this would not be possible in 
the present study since information about timing of the last 
dose is not available and the results of any pharmacokinetic 
data would therefore be difficult to interpret. 
In conclusion, this retrospective analysis of a large pro-
spective observational database shows that virological sup-
pression with DBPI was reached in 64% in a highly 
antiretroviral drug-exposed population. These regimens seem 
to be well-tolerated with less than 20% toxicity, and hyper-
lipidemia did not seem to occur at a statistic;ally significant 
level. Moreover, 73% of patients tolerated the DBPI for a 
median of 2.2 years [IQR, 1.2-3.9]. Even though potentially 
safer alternatives are currently marketed in the treatment-
experienced patients, OBPI salvage regimens may only be the 
one available for most people in resource-poor settings. Non 
clade-B viruses are well represented in the SHCS database,45 
but in our overall study population, 45 (14%) of the subtyped 
viruses were non-B viruses and 1 patient was infected with 
HIV~2. However, there is no evidence in the literature that 
non-B viruses and HIV-2 would differ in their response to 
DBPI. Therefore this salvage strategy deserves further con-
sideration in resource-poor settings as resistance to first-line 
regimens, and particularly to the entire class of NRTI and first 
generation NNRTis, seems to develop at a high rate due to the 
absence of viral load monitoring. 26--28 Therefore, just as 
heavily experienced patients in the SHCS had a benefit from 
DBPI regimens at time when other therapies were not avail-
able, these regimens may also represent à bridge of survival 
before more expensive drugs, widespread viral load testing, 
7 
and genotypes are widely made available for patients in re-
source-limited settings who fail current treatments. 
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